Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

Is there adequate evidence for the use of PARPi in combination with ARSI for BRCA+/HRR mutated mCRPC as compared to sequential therapy?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · Beth Israel Deaconess Medical Center

This question is phrased perfectly: the important consideration is whether sequential therapy would be just as good, i.e. the "old" standard of care. Unfortunately, this is not how the three trials cited above were designed. Control-arm HRRm patients were assumed to have access to PARPi post-protoco...

How are you choosing between ipilimumab/nivolumab versus platinum/pemetrexed for unresectable epithelioid mesotheliomas?

2
2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Michigan

Although the combination of ipi/nivo has been approved for all unresectable mesotheliomas, the benefit was much more impressive in the NON-epithelioid histologies. Therefore, for patients with epithelioid mesothelioma, I follow the NCCN recommendations where I would discuss both platinum/pemetrexed ...

When do you recommend PD-L1 testing for patients with recurrent cervical cancer?

1 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · University of California Irvine Medical Center

I think getting the testing done as soon as possible is best because very few patients will only need first line therapy. This way, there is less of a delay at the time of progression following/during first-line therapy.

How have you incorporated ctDNA into the clinical management of patients with gynecologic cancers?

5
2 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · The Ohio State University College of Medicine

ctDNA certainly is increasing rapidly in oncology and has been led by several other disease sites. I think right now, GYN oncology is figuring out how to incorporate this in our care to meaningfully impact our patients. I have not incorporated ctDNA in my practice routinely, but do see the role of i...

Would you consider neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer who are cisplatin-ineligible?

2
2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Virginia

We have level 1 evidence supporting neoadjuvant cisplatin-based chemotherapy followed by cystectomy, there is no evidence supporting non-cisplatin based chemotherapy. Patients unfit for cisplatin should proceed directly to surgery.

What criteria do you use in deciding whether or not to treat the pelvis in prostate cancer?

14
6 Answers

Mednet Member
Mednet Member
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center

NRG/RTOG 0924 - The end of elective nodal RT in localized prostate cancer? Top line results: NRG/RTOG 0924 is a very large phase III randomized trial powered for overall survival (OS) to determine if there is a benefit of the addition of whole pelvic radiotherapy (WPRT) to prostate RT plus ADT. This...

How do you monitor response for stage III NSCLC patients receiving consolidation immunotherapy?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · Cedars-Sinai Medical Center

Generally, the first imaging post chemoradiation (CRT) would have been performed about 6-8 weeks following completion, and this has changed as we start durvalumab within 42 days following CRT. I perform a baseline CT chest prior to starting durvalumab. I proceed to monitor with CT chest about every ...

How do you time re-staging studies and adjuvant durvalumab for stage III NSCLC treated with definitive cCRT?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Cedars-Sinai Medical Center

In the PACIFIC study, 713 patients who received at least 2 cycles of platinum-based chemotherapy with radiation (CRT) and did not develop disease progression were randomly assigned in a 2:1 manner to receive durvalumab at 10 mg/kg every 2 weeks up to 12 months or placebo. Randomization took place be...

For patients with inoperable stage III NSCLC who are unable to receive or refuse definitive chemoradiation, how do you decide among radiation alone, pembrolizumab alone, or radiation followed by either pembrolizumab or durvalumab?

5
5 Answers

Mednet Member
Mednet Member
Medical Oncology · Wexner Medical Center at The Ohio State University

So, this is a challenging question – actually two questions – 1) unable, 2) refuse. With respect to unable, this typically would (I assume, and in my practice) refer to patients whose functional status is sufficiently poor to prevent one from giving chemotherapy along with radiation. Note that esse...

When do you start adjuvant radiation with areas of delayed wound healing after reduction mammoplasty?

6
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · UNC School of Medicine

Great question. I have cared for many patients with delayed healing post-lumpectomy (e.g., from infection, wound failure, etc.), and that experience is likely pertinent to the mammoplasty setting. Once the wound is open, it is going to take many weeks/months to “fully” heal, and it is not practical...